Endovasc’s licenses and patents describe technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents for the treatment of vascular dysfunction related to heart disease.
Pending completion of FDA clinical trials, these products and technologies have the potential to:
· Dramatically improve patient quality of life.
· Reduce the need for costly repeat procedures for cardiac patients.
· Reduce healthcare costs.
Trademarked products include: (click on the links below)
• Liprostin™
• PROStent™
Endovasc has entered into two joint venture agreements with TissueGen, Inc. for the development of the "next generation" of drug-eluting stents which will be comprised of a biocompatible, biodegradable, Resorbable material: (click on the links below)
• Endovasc-TissueGen Research Sponsors, LLC
• Endovasc-TissueGen-Blumberg Research Sponsors, LLC
Endovasc has also developed a nutraceutical product with the promise to enhance muscle mass and reduce body weight.
• Nutraceutical Development Corporation
Endovasc, Inc.
550 Club Drive, Suite 345
Montgomery, TX 77316
936.582.5920
email: robjohnson@endovasc.com
